Diane Gosselin is a leader who has been passionately committed to the financing of biomedical R&D for over 30 years. President and Chief Executive Officer of CQDM between 2012 and 2025, she joined the organization in 2008 as Vice-President, Research and Business Development where she has been actively involved in the creation of CQDM. She has demonstrated the relevance and the value of CQDM’s model in building an impressive portfolio of 150 outstanding technologies that strongly impact biopharmaceutical research and mobilizes more than 120 SMEs. She has raised $375M in funding at CQDM and has developed several local and international partnerships that have generated another $225M to further support innovative R&D across Canada. Prior to CQDM, she worked at the Fonds de Solidarité FTQ where she managed an investment portfolio and helped several companies implement their drug development strategy. At PROCREA BioSciences, she led the research team that developed the first worldwide non-invasive diagnostic test for endometriosis. She took part in several Life Sciences matters, notably as a member of focus groups, investment Committees, and as a Board member (CQDM, Canadian Cancer Society, Ontario Genomics, Medicament Québec, INRS University, Montreal InVivo, Canadian Institutes of Health Research, BioteCanada, CQIB, Fonds Bio-Innovation, Cardianove). She is currently member of the Board of CATALIS. She holds a Ph.D. in microbiology and immunology from Université de Montréal, as well as an Executive MBA from Université du Québec à Montréal (UQAM) and Université Paris-Dauphine. Also, she has completed the certification Corporate Governance from Université Laval.
